Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Digestive Disease Specialists, Inc. has selected its ProVation MD software for gastroenterology procedure documentation and coding.

9 Dec 2010

Researchers to address HRQOL issues for pediatric patients with IBD at annual conference

The management of children with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis has evolved significantly over the past decade. With a surge of pediatric research in the field, quality of life has become an important focus of study, as indicated by the number of related abstracts that will be presented at the 2010 Advances in Inflammatory Bowel Diseases, the Crohn's & Colitis Foundation's Clinical & Research Conference beginning tomorrow in Hollywood, Florida.

9 Dec 2010

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes. Development of the software, the Type 1 Diabetes PhysioLab- Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

9 Dec 2010

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.

9 Dec 2010

New endoscope aids in early detection and diagnosis of inflammatory bowel disease.

An international team of researchers led by the University of East Anglia (UEA) have developed a new kind of endoscope to aid the early detection and diagnosis of inflammatory bowel disease.

7 Dec 2010

New tool for predicting disease course in children with Crohn's disease

A new study published in the journal Inflammatory Bowel Diseases develops a computer based visual tool that can be used in “real time” to show pediatric Crohn’s disease (CD) patients’ predicted disease course and how this might be influenced by different treatment options.

6 Dec 2010

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

30 Nov 2010

Kenneth Rainin announces 2011 Innovator Awards Program for Inflammatory Bowel Disease

The Kenneth Rainin Foundation announced today its 2011 Innovator Awards Program for Inflammatory Bowel Disease. The Program, now in its second year, is designed to accelerate the pace of discovery in IBD research.

30 Nov 2010

DATATRAK applauds Cosmo Pharmaceuticals for positive top-line results from budesonide MMX

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today publically congratulated its sponsor partner Cosmo Pharmaceuticals S.p.A. who last week announced positive top-line results from their second pivotal Phase III clinical study which was conducted in the EU utilizing DATATRAK's unified eClinical product suite and services team to evaluate the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate ulcerative colitis.

30 Nov 2010

RCSI researchers discover potential new target for diarrhoea associated intestinal diseases

A study by researchers in the Royal College of Surgeons in Ireland (RCSI) has uncovered a potential new target for the treatment of a range of intestinal diseases that are associated with diarrhoea. Current medications are often ineffective and can have serious side effects so this discovery gives hope for the development of new treatments for sufferers of intestinal disease.

30 Nov 2010

Immunity-enhancing probiotics may be the best line of defense for good health

Good bacteria, bad bacteria, billions of bacteria—sounds downright germy. But the truth is that research in gut health is germinating more insight into the role bacteria, also known as "probiotics," play in our overall health and wellness.

25 Nov 2010

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

22 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.

9 Nov 2010

Omthera initiates ECLIPSE study for treatment of high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.

9 Nov 2010

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Athersys, Inc. announced today that the U.S. Food and Drug Administration (FDA) has authorized commencement of a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem, Athersys' allogeneic investigational cell therapy product, for the potential treatment of ulcerative colitis.

8 Nov 2010

Study suggests bacterial products contribute to autoimmune diseases

Researchers are using 21st century technologies to investigate the century old hypothesis that certain autoimmune diseases, including rheumatoid arthritis, are caused by bacteria living in the human body and will present their initial data this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program recognized Quanterix's Single Molecule Array (SiMoA™) platform as a promising advance that will improve diagnosis and treatment of disease while reducing healthcare costs.

3 Nov 2010

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Researchers to address HRQOL issues for pediatric patients with IBD at annual conference

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

New endoscope aids in early detection and diagnosis of inflammatory bowel disease.

New tool for predicting disease course in children with Crohn's disease

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

Kenneth Rainin announces 2011 Innovator Awards Program for Inflammatory Bowel Disease

DATATRAK applauds Cosmo Pharmaceuticals for positive top-line results from budesonide MMX

RCSI researchers discover potential new target for diarrhoea associated intestinal diseases

Immunity-enhancing probiotics may be the best line of defense for good health

Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Omthera initiates ECLIPSE study for treatment of high triglycerides

FDA authorizes Athersys' MultiStem Phase II clinical trial for ulcerative colitis

Study suggests bacterial products contribute to autoimmune diseases

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in